Methods of treatment patients with androgenetic alopecia based on reference of Department of Dermatology in Cracow
- PMID: 30830894
Methods of treatment patients with androgenetic alopecia based on reference of Department of Dermatology in Cracow
Abstract
Androgenetic alopecia (AGA in men/female pattern hair loss FPHL in women) has been associated with the most frequent culprit of hair loss concerning both men and women. It may be viewed as chronic, progressive, non scarring type of hair loss. The main factor in its pathophysiological mechanism plays genetic susceptibility to androgens of certain individuals. Increased level of androgens shown to be the cause in men, whereas in women this level may be elevated or normal. For the management of the condition topical treatment with minoxidil has been approved, as well as orally administered finasteryd, spironolakton or dutasteride.
Aim: The main objective of this research project was to study the patients with AGA in terms of gender, age, prescribed treatment and hormone dysfunctions.
Materials and methods: The analyzed population consisted of 104 patients treated in dermatology department in Cracow in three years period (2015-2018) for AGA. Initially, demographic characteristics and treatment were tested. The next step of the analysis was the comparison of groups according to gender and, what is more among women according to age (up to 45 and >45 years of age). Statistical analysis was performed with U Mann-Whitney and Chi square Pearsons tests.
Results: The majority of patients participating in the study were women (87,5%). The average age of the study population was 45,5±15,5 years of age. The most frequently ordered medicine was minoxidil 5% solution (82,2% of patients), besides polytherapy of two medicines were applied in 45,8% of patients. In the study group hypothyroidism was observed in 10.6% of patients. The examined group of women were older than men (48.3 vs. 25.8 years; p<0.0001). Male patients were more often ordered systemic treatment (52.9 vs.15,4%; p=0.0012), whereas topical treatment was more often applied to women (94.5 vs. 69.2; p=0.0024). Women usually were ordered more than one medicine in contrast to men (44.0 vs. 15.4%; p=0.0495). Therefore no significant difference between women up to 45 and >45 years of age was observed.
Conclusions: Statistically significant occurrence of hypothyroidism was observed. Therefore this connection requires further studies. Other endocrinological dysfunctions like acne, hirsutism or menstrual disorder were relatively rare.
Keywords: AGA; FPHL; alopecia; androgenetic alopecia; finasteride; hair loss; minoxidil; spironolactone; treatment.
© 2019 MEDPRESS.
Similar articles
-
Androgenetic alopecia: an evidence-based treatment update.Am J Clin Dermatol. 2014 Jul;15(3):217-30. doi: 10.1007/s40257-014-0077-5. Am J Clin Dermatol. 2014. PMID: 24848508 Review.
-
A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia.J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2257-2263. doi: 10.1111/jdv.15171. Epub 2018 Jul 20. J Eur Acad Dermatol Venereol. 2018. PMID: 29972712 Clinical Trial.
-
Androgenetic alopecia and current methods of treatment.Acta Dermatovenerol Alp Pannonica Adriat. 2005 Mar;14(1):5-8. Acta Dermatovenerol Alp Pannonica Adriat. 2005. PMID: 15818439 Review.
-
The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral finasteride in women with androgenic alopecia, female and male hair loss patterns: A blinded randomized clinical trial.J Cosmet Dermatol. 2024 Feb;23(2):543-551. doi: 10.1111/jocd.15979. Epub 2023 Aug 31. J Cosmet Dermatol. 2024. PMID: 37650533 Clinical Trial.
-
Topical fulvestrant solution has no effect on male and postmenopausal female androgenetic alopecia: results from two randomized, proof-of-concept studies.Br J Dermatol. 2008 Jan;158(1):109-15. doi: 10.1111/j.1365-2133.2007.08276.x. Epub 2007 Nov 6. Br J Dermatol. 2008. PMID: 17986309 Clinical Trial.
Cited by
-
The hydroxypropyl-β-cyclodextrin-minoxidil inclusion complex improves the cardiovascular and proliferative adverse effects of minoxidil in male rats: Implications in the treatment of alopecia.Pharmacol Res Perspect. 2020 Jun;8(3):e00585. doi: 10.1002/prp2.585. Pharmacol Res Perspect. 2020. PMID: 32378360 Free PMC article.
-
Research Trends and Hotspots in Female Pattern Hair Loss: A Bibliometric Study.J Cosmet Dermatol. 2025 Aug;24(8):e70369. doi: 10.1111/jocd.70369. J Cosmet Dermatol. 2025. PMID: 40736064 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Miscellaneous